Cure TV

Dr. Sheldon Marc Feldman explores Reiki’s potential to reduce stress and anxiety for patients undergoing breast cancer surgery at Montefiore Einstein.

Dr. Nicolas Girard discussed the current treatment options for patients with EGFR-mutant lung cancer, including emerging combination regimens.

Dr. Fred Hirsch highlighted how knowledge of the molecular characteristics of non-small cell lung cancer enhances understanding of the disease.

In EGFR-mutated non-small cell lung cancer Tagrisso with pemetrexed and chemotherapy was associated with an improvement in survival.

The New Jersey retreat is free for women during and two years after cancer treatment.

Alison Ankiewicz explains how pelvic physical therapy restores tissue, sexual function and emotional confidence for patients after cancer treatment.

Dr. Mary B. Beasley discusses evolving role of pathologists in lung cancer care, highlighting how emerging technologies may shape the future of the field.

Heather Ann Yonker expands on strategies for maintaining food safety in the home, particularly for patients with compromised immune systems due to cancer.

Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone.

Dr. Sandip Patel discusses findings from a real-world study of biomarker testing in early-stage resected non-small cell lung cancer in the U.S.

Dr. Patrick J. Hensley shares the treatment landscape of non-muscle-invasive bladder, as well as how individual risk factors can alter treatment options.

Dr. Patrick Wen discussed with CURE how Modeyso treats diffuse midline glioma, and what unmet needs remain for patients now that the therapy is available.

Dr. Alexander Spira explained the difference between a clinical trial and a real-world study in a CURE interview for patients with lung cancer.

Ibtrozi may become the new standard for ROS1-mutated lung cancer, with phase 2 data showing safer, longer-lasting benefits for patients.

Targeted therapies have changed non-small cell lung cancer care, but new side effects, like weight gain, are emerging, says Dr. Lorenzo Belluomini.

Dr. Jacob A. Sands shares how patients with lung cancer can interpret clinical trial results and how these findings translate to treatment decisions.

Dr. David A. Taub sat down with CURE for an interview in honor of Prostate Cancer Awareness Month, observed annually each September.

CURE spoke with chief medical officer Gwen Nichols and partner Suleika Jaouad about the inclusive rebranding.

After years of chronic cough and misdiagnosed infections, a 2016 stage 4 ALK-positive lung cancer diagnosis led to targeted therapy that has helped since.

Heather Ann Yonker, emphasizes the importance of food safety practices for patients with cancer, particularly those with weakened immune systems.

Dr. Daniel P. Petrylak discussed recent developments in prostate cancer care, emphasizing the importance of genetic testing and personalized treatment.

Dr. Prithviraj Bose discussed the current treatment landscape for myeloproliferative neoplasms, a group of rare blood cancers; he focused on myelofibrosis.

Patients need long-term monitoring after gastrointestinal stromal tumor surgery, with some requiring extra treatment or genetic testing to lower recurrence risk.

Dr. Christina Cho highlights the Adult Stem Cell Transplant and Cellular Therapy Program for its innovative research and compassionate, multidisciplinary team.

After receiving a breast cancer diagnosis at 29, Amanda Davis wants other young adults who are patients to know that “brighter days are coming.”

Kidney cancer care has seen advances over the past few decades, reflecting both improved diagnostic capabilities and less invasive treatment approaches.

Obtaining an accurate diagnosis is a crucial first step in kidney cancer care, according to Dr. Shuanzeng “Sam” Wei of Fox Chase Cancer Center.